WARNING: We do not support Internet Explorer. It is not secure and will not work correctly. Please come back using a newer web browser.

Facts and Fiction about Colistin from Clinical and Public Health Perspectives

Free On Demand: Colistin Webinar

Facts and Fiction about Colistin from Clinical and Public Health Perspectives

Recorded on September 20, 2016

The resurrection of colistin as a last resort drug for treatment of multidrug resistant gram-negative bacilli (MDR GNB) has prompted clinicians and researchers to understand how this agent performs in the test tube and in the patient. Much has been learned but some aspects surrounding the use of colistin remain a mystery. This session will focus on colistin testing and reporting, colistin resistance due to mcr-1 and other resistance mechanisms and colistin dosing and administration. The goal is to bring laboratorians, clinicians, pharmacists and public health personnel up to date on the role of colistin in combatting infections due to MDR GNB in today’s healthcare settings.


  • List options for testing and reporting colistin for guiding treatment decisions and monitoring resistance
  • Discuss public health considerations for mcr-1-mediated resistance and other mechanisms of colistin resistance
  • Describe clinical parameters including pharmacokinetics/pharmacodynamics (PK/PD) for using colistin for the treatment of MDR GNB

Members: FREE

Nonmembers: FREE
Log in/sign up to see price and add to cart


Date of Webinar: September 20, 2016

Free On Demand: Colistin Webinar Additional Details


  • Romney M. Humphries, PhD, D(ABMM), Section Chief, Clinical Microbiology, UCLA David Geffen School of Medicine
  • Jean B. Patel, PhD, D(ABMM), Deputy Director, Office of Antimicrobial Resistance, Centers for Disease Control and Prevention
  • David P. Nicolau, PharmD, FCCP, FIDSA, Director Hartford Hospital